🔴 Gossamer Bio is trading 7.1% down with no clear catalyst identified

Gossamer Bio is trading at $11.01, down 7.09%, with no clear company-specific catalyst identified for the decline.

• The September 23 seralutinib FDA application news predates the October 1 move and does not explain it.
• Treasury yields and macroeconomic uncertainty were notable themes, but major-index moves were mixed and modest, leaving broader-market pressure an unclear explanation.